94. 原発性硬化性胆管炎 Primary sclerosing cholangitis Clinical trials / Disease details
臨床試験数 : 148 / 薬物数 : 118 - (DrugBank : 39) / 標的遺伝子数 : 18 - 標的パスウェイ数 : 141
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05376228 (ClinicalTrials.gov) | February 1, 2022 | 11/5/2022 | A Systems Biology Approach for Identification of Host and Microbial Mechanisms and Druggable Targets for the Treatment of PSC-IBD | A Systems Biology Approach for Identification of Host and Microbial Mechanisms and Druggable Targets for the Treatment of PSC-IBD | Inflammatory Bowel Diseases;Primary Sclerosing Cholangitis | Drug: Oral Vancomycin | University Hospital Birmingham NHS Foundation Trust | NULL | Recruiting | 18 Years | N/A | All | 15 | United Kingdom | |
| 2 | NCT03046901 (ClinicalTrials.gov) | December 7, 2016 | 31/1/2017 | Vancomycin Treatment in Recurrent PSC in Liver Transplant Patients | Oral Vancomycin Treatment in Recurrent Primary Sclerosing Cholangitis in Liver Transplant Recipients | Primary Sclerosing Cholangitis;Post- Orthotopic Liver Transplantation | Drug: Vancomycin | Ochsner Health System | NULL | Withdrawn | N/A | N/A | All | 0 | N/A | United States |
| 3 | NCT02605213 (ClinicalTrials.gov) | September 2015 | 31/10/2015 | Effect and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis Patients | Evaluation of Effectiveness and Safety of Oral Vancomycin in Treatment of Primary Sclerosing Cholangitis. | Primary Sclerosing Cholangitis | Drug: Vancomycin;Drug: Placebo | Tehran University of Medical Sciences | NULL | Recruiting | 18 Years | 60 Years | Both | 30 | Phase 4 | Iran, Islamic Republic of |
| 4 | NCT02464020 (ClinicalTrials.gov) | July 2015 | 29/5/2015 | A Pilot Study to Characterize Bile Acid Metabolism and Dysbiosis in Primary Sclerosing Cholangitis | A Pilot Study to Characterize Bile Acid Metabolism and Dysbiosis in Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis;Inflammatory Bowel Disease | Drug: Vancomycin | University of Minnesota | NULL | Completed | 18 Years | 80 Years | All | 8 | Phase 1 | United States |
| 5 | EUCTR2009-018034-11-SE (EUCTR) | 29/04/2013 | 21/06/2011 | Open pilot study of treatment with an antibiotic called vancomycin to children and adolescents with chronic inflammation of the bile ducts, called primary sclerosing cholangitis (PSC) | Open pilot study of treatment with vancomycin to children and adolescents with primary sclerosing cholangitis - vanco-psc | Primary Sclerosing Cholangitis (PSC) is a progressive disease of the biliary system which might lead to increased risk of cholangiocancer. PSC constitutes a common indication for adult liver transplantation (ltx). In 80% of cases PSC is associated with inflammatory bowel disease (IBD), while 3-5 % of patients with colonic IBD, suffer from the disease. The conservative treatment options are few. There is a relatively high risk of recurrency after ltx.;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Trade Name: Vancomycin Product Name: vancomycin Trade Name: vancomycin Product Name: Vancomycin | Karolinska Institutet | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 20 | Sweden | |||
| 6 | NCT01802073 (ClinicalTrials.gov) | January 2012 | 21/2/2013 | Primary Sclerosing Cholangitis With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects | Treatment of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects | Primary Sclerosing Cholangitis | Drug: Oral Vancomycin | Stanford University | NULL | Completed | 1 Year | N/A | All | 34 | Phase 3 | United States |
| 7 | NCT02137668 (ClinicalTrials.gov) | July 2010 | 12/5/2014 | Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin | The Human Gastrointestinal Tract Microbiota in the Setting of Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin | Primary Sclerosing Cholangitis;Biliary Atresia | Drug: Oral Vancomycin | Sacramento Pediatric Gastroenterology | NULL | Recruiting | N/A | 40 Years | Both | 200 | Phase 1 | United States |
| 8 | NCT01085760 (ClinicalTrials.gov) | February 2010 | 10/3/2010 | A Pilot Study of Vancomycin or Metronidazole in Patients With Primary Sclerosing Cholangitis | A Pilot Study of Vancomycin or Metronidazole in Patients With Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis | Drug: Vancomycin;Drug: Metronidazole | Mayo Clinic | PSC Partners Seeking a Cure Foundation | Completed | 18 Years | 75 Years | All | 35 | Phase 1 | United States |
| 9 | NCT01322386 (ClinicalTrials.gov) | May 2007 | 10/2/2011 | Gastrointestinal Microbiota in Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin | The Human Gastrointestinal Tract Microbiota in the Setting of Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin. | Primary Sclerosing Cholangitis;Biliary Atresia | Drug: Vancomycin | Stanford University | NULL | Completed | 1 Month | 20 Years | All | 32 | Phase 1 | NULL |